Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

Therapeutic vaccines against tobacco addiction.

Fahim RE, Kessler PD, Kalnik MW.

Expert Rev Vaccines. 2013 Mar;12(3):333-42. doi: 10.1586/erv.13.13. Review.

PMID:
23496672
2.

The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.

Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, Brauer R, Kessler PD, Kalnik MW, Fahim RE, van Schayck OC.

BMC Public Health. 2012 Dec 6;12:1052. doi: 10.1186/1471-2458-12-1052.

3.

Nicotine vaccines.

Fahim RE, Kessler PD, Fuller SA, Kalnik MW.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):905-15. Review.

PMID:
22229310
4.

Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, Kessler PD, Niknian M, Kalnik MW, Rennard SI.

Clin Pharmacol Ther. 2011 Mar;89(3):392-9. doi: 10.1038/clpt.2010.317. Epub 2011 Jan 26.

5.

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.

Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M; CARE-2 Investigators.

Am J Kidney Dis. 2008 Jun;51(6):952-65. doi: 10.1053/j.ajkd.2008.02.298. Epub 2008 Apr 18.

PMID:
18423809
6.

A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.

Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A, Macko J, Kessler PD, Rasmussen HS, Epstein SE, Kornowski R.

Catheter Cardiovasc Interv. 2006 Sep;68(3):372-8.

PMID:
16892433
7.

Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.

Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS.

Gene Ther. 2006 Nov;13(21):1503-11. Epub 2006 Jun 22.

PMID:
16791287
8.

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.

Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR.

Clin Cancer Res. 2004 Sep 1;10(17):5747-53.

9.

Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).

Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D.

Gene Ther. 2004 Mar;11(6):512-21.

PMID:
14999223
10.

Reflective journaling: developing an online journal for distance education.

Kessler PD, Lund CH.

Nurse Educ. 2004 Jan-Feb;29(1):20-4.

PMID:
14726795
11.

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.

Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH.

Circulation. 2003 Oct 21;108(16):1933-8. Epub 2003 Sep 22.

12.

Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.

Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Kibbe M, Kovesdi I, Brough DE, Topol EJ, Lincoff AM.

Mol Ther. 2003 May;7(5 Pt 1):597-603.

PMID:
12718902
13.

Cell therapy in the heart: cell production, transplantation, and applications.

Cahill KS, Toma C, Pittenger MF, Kessler PD, Byrne BJ.

Methods Mol Biol. 2003;219:73-81. No abstract available.

PMID:
12596999
14.

Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

Fraites TJ Jr, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I, Pauly DF, Raben N, Plotz PH, Powers SK, Kessler PD, Byrne BJ.

Mol Ther. 2002 May;5(5 Pt 1):571-8.

15.

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.

Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C.

Hum Gene Ther. 2002 Jan 1;13(1):65-100.

PMID:
11779413
16.

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.

Hum Gene Ther. 2002 Jan 1;13(1):15-63.

PMID:
11779412
17.

Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.

Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD.

Circulation. 2002 Jan 1;105(1):93-8.

18.

Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.

Pauly DF, Fraites TJ, Toma C, Bayes HS, Huie ML, Hirschhorn R, Plotz PH, Raben N, Kessler PD, Byrne BJ.

Hum Gene Ther. 2001 Mar 20;12(5):527-38.

PMID:
11268285
19.

Myoblast cell grafting into heart muscle: cellular biology and potential applications.

Kessler PD, Byrne BJ.

Annu Rev Physiol. 1999;61:219-42. Review.

PMID:
10099688
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk